EV Biologics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of EV Biologics generated cash of -$3,282,724, which is more than the previous year. Cash used in financing activities reached the amount of -$7,724,088 last year. Net change in cash is therefore -$208,295.
Cash Flow
| 2013 | 11.35M | -16.15M | 6.13M |
|---|---|---|---|
| 2014 | 12.11M | 1.65M | 176.53K |
| 2015 | 6.20M | -1.99M | -7.59M |
| 2016 | 13.27M | -36.60M | 10.62M |
| 2017 | 1.54M | -1.92M | -450.64K |
| 2020 | 97.68K | 0 | 4.81K |
| 2021 | 697.91K | -21.67M | 21.68M |
| 2022 | -20.84M | 19.78M | 1.99M |
| 2023 | -3.28M | 10.79M | -7.72M |
YECO Cash Flow Statement (2013 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 335.07K | 600K | 102.5K | -2 | 2.73M | 16.47M | 19.73M | 5.79M | 4.32M |
Operating activities | |||||||||
Net income | -1.26M | -21.05M | -387.69K | -98.96K | -551.58K | -53.19M | 8.67M | 10.69M | 10.04M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 686.99K | 2.21M | 1.75M | 1.38M | 1.05M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 162.36K | 534.23K | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 162.36K | 534.23K | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -15.31K | -131.1K | -118.9K | 0 | -1.35M | -1.12M | -4.08M | -1.07M | -347.38K |
Inventories | 0 | 0 | 0 | 0 | 147.65K | -30.98K | 60.56K | -106.55K | 1.15M |
Accounts payable | -102.28K | 206.82K | 0 | 0 | 623.80K | 127.93K | -107.34K | 293.59K | -396.53K |
Cash generated by operating activities | -3.28M | -20.84M | 697.91K | 97.68K | 1.54M | 13.27M | 6.20M | 12.11M | 11.35M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -39.43K | 0 | -19.26M | 0 | -1.92M | -36.62M | -2.02M | -950.49K | -14.11M |
Acquisitions Net | 0 | 6.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 10.79M | 19.78M | -21.67M | 0 | -1.92M | -36.60M | -1.99M | 1.65M | -16.15M |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 0 | 4.81K | 0 | 11.51M | 11.51M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -21.68M | 0 | 0 | -6.50M | -2.30M | -8.77M | -12.70M |
Cash used in financing activities | -7.72M | 1.99M | 21.68M | 4.81K | -450.64K | 10.62M | -7.59M | 176.53K | 6.13M |
Net Change In Cash | -208.29K | -264.92K | 497.5K | 102.5K | -920.63K | -13.73M | -3.26M | 13.94M | 1.47M |
Cash at end of period | 126.78K | 335.07K | 600K | 102.5K | 1.81M | 2.73M | 16.47M | 19.73M | 5.79M |